Total Payments
$493,324
2024 Payments
$87,875
Companies
36
Transactions
647
Medicare Patients
11,895
Medicare Billing
$9.9M
Payment Breakdown by Category
Other$258,079 (52.3%)
Consulting$121,691 (24.7%)
Travel$46,213 (9.4%)
Research$41,140 (8.3%)
Food & Beverage$26,201 (5.3%)
Education$0.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $251,079 | 56 | 50.9% |
| Consulting Fee | $121,691 | 45 | 24.7% |
| Travel and Lodging | $46,213 | 110 | 9.4% |
| Unspecified | $41,140 | 21 | 8.3% |
| Food and Beverage | $26,201 | 409 | 5.3% |
| Honoraria | $7,000 | 5 | 1.4% |
| Education | $0.99 | 1 | 0.0% |
Payments by Type
General
$452,184
626 transactions
Research
$41,140
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $230,273 | 240 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $83,846 | 62 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $51,784 | 59 | $0 (2024) |
| Alimera Sciences, Inc. | $32,817 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $26,329 | 32 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $17,227 | 32 | $0 (2024) |
| F. Hoffmann-La Roche AG | $13,909 | 12 | $0 (2024) |
| Allergan, Inc. | $7,212 | 29 | $0 (2021) |
| Ocular Therapeutix, Inc. | $6,969 | 19 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $4,203 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,875 | 109 | Apellis Pharmaceuticals, Inc. ($42,612) |
| 2023 | $71,674 | 93 | Genentech USA, Inc. ($33,584) |
| 2022 | $94,779 | 103 | Genentech USA, Inc. ($68,869) |
| 2021 | $31,755 | 56 | Regeneron Healthcare Solutions, Inc. ($16,174) |
| 2020 | $39,738 | 38 | Regeneron Healthcare Solutions, Inc. ($27,367) |
| 2019 | $58,612 | 89 | Genentech USA, Inc. ($29,278) |
| 2018 | $65,547 | 87 | Genentech USA, Inc. ($48,190) |
| 2017 | $43,344 | 72 | Genentech USA, Inc. ($32,861) |
All Payment Transactions
647 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $25.14 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/12/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $117.67 | General |
| Category: Ophthalmology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $120.57 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $3.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/06/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Ophthalmology | ||||||
| 10/29/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Ophthalmology | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Ophthalmology | ||||||
| 10/16/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.04 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/02/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $90.18 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/02/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $835.00 | Research |
| Study: A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | ||||||
| 09/25/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | Cash or cash equivalent | $33.11 | General |
| Category: Ophthalmology | ||||||
| 09/25/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $10.86 | General |
| Category: Ophthalmology | ||||||
| 09/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,739.25 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 09/14/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $30.66 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/11/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,933.00 | General |
| Category: Ophthalmology | ||||||
| 09/10/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $58.31 | General |
| Category: Ophthalmology | ||||||
| 09/04/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $2,838.00 | General |
| Category: Ophthalmology | ||||||
| 08/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $762.24 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Iluvien Study | Alimera Sciences, Inc. | $31,003 | 15 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $3,515 | 1 |
| A DOUBLE- MASKED, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL ADMINISTRATION OF VEGF TRAP-EYE IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $2,970 | 1 |
| A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS, A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS | F. Hoffmann-La Roche AG | $1,942 | 1 |
| A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | F. Hoffmann-La Roche AG | $1,256 | 2 |
| A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema | Regeneron Pharmaceuticals, Inc. | $453.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,915 | 56,528 | $6.4M | $2.4M |
| 2022 | 19 | 3,044 | 15,543 | $6.3M | $2.2M |
| 2021 | 18 | 3,027 | 12,426 | $7.8M | $2.6M |
| 2020 | 17 | 2,909 | 12,933 | $8.2M | $2.8M |
Total Patients
11,895
Total Services
97,430
Medicare Billing
$9.9M
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 209 | 49,980 | $3.5M | $1.4M | 41.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 66 | 462 | $924,000 | $318,498 | 34.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 85 | 1,316 | $1.1M | $235,197 | 22.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 388 | 1,258 | $257,890 | $123,085 | 47.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 618 | 950 | $237,500 | $80,600 | 33.9% |
| 92134 | Imaging of retina | Office | 2023 | 937 | 1,637 | $130,960 | $47,932 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 253 | 366 | $95,160 | $33,071 | 34.8% |
| J3490 | Unclassified drugs | Office | 2023 | 24 | 90 | $34,800 | $17,746 | 51.0% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 12 | 75 | $33,750 | $16,068 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 117 | 117 | $38,610 | $13,411 | 34.7% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 23 | 29 | $37,265 | $10,545 | 28.3% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 28 | 32 | $21,120 | $7,938 | 37.6% |
| 76510 | 1d and 2d ultrasound scan of eye tissue and structures | Office | 2023 | 39 | 53 | $9,540 | $2,577 | 27.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 21 | 46 | $9,200 | $2,566 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 26 | $4,680 | $1,800 | 38.5% |
| 76513 | Ultrasound scan of eye using water bath method | Office | 2023 | 17 | 20 | $3,800 | $1,006 | 26.5% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 28 | 35 | $4,375 | $981.48 | 22.4% |
| 92250 | Photography of the retina | Office | 2023 | 18 | 22 | $1,650 | $642.07 | 38.9% |
| 92285 | Photography of content of eyes | Office | 2023 | 12 | 14 | $560.00 | $199.99 | 35.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 230 | 3,385 | $2.7M | $763,050 | 28.2% |
| J3490 | Unclassified drugs | Office | 2022 | 159 | 362 | $1.2M | $517,424 | 41.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 85 | 498 | $996,000 | $351,494 | 35.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 87 | 6,840 | $478,800 | $204,115 | 42.6% |
| 67028 | Injection of drug into eye | Office | 2022 | 376 | 1,256 | $257,480 | $124,942 | 48.5% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 635 | 940 | $235,000 | $78,838 | 33.5% |
About Dr. Ivan Suner, M.D
Dr. Ivan Suner, M.D is a Ophthalmology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164522793.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ivan Suner, M.D has received a total of $493,324 in payments from pharmaceutical and medical device companies, with $87,875 received in 2024. These payments were reported across 647 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($251,079).
As a Medicare-enrolled provider, Suner has provided services to 11,895 Medicare beneficiaries, totaling 97,430 services with total Medicare billing of $9.9M. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology
- Location Tampa, FL
- Active Since 09/24/2006
- Last Updated 04/01/2010
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1164522793
Products in Payments
- Lucentis (Biological) $131,162
- EYLEA (Biological) $64,112
- Syfovre (Drug) $63,928
- VABYSMO (Drug) $60,845
- ILUVIEN (Drug) $31,436
- Vabysmo (Drug) $17,653
- Susvimo (Drug) $10,169
- BROLUCIZUMAB (Drug) $8,521
- Non-Covered Product (Drug) $7,790
- OZURDEX (Drug) $7,070
- DEXTENZA (Drug) $3,979
- EYLEA HD (Biological) $3,874
- SUSVIMO (Drug) $3,282
- Izervay (Drug) $3,169
- BEOVU (Drug) $2,804
- YUTIQ (Drug) $2,357
- XIPERE (Drug) $2,195
- Jetrea (Drug) $1,250
- EYLEA AFLIBERCEPT INJECTION (Biological) $974.97
- STELLARIS PC (Device) $605.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Tampa
Dr. Pedram Hamrah, M.d, M.D
Ophthalmology — Payments: $198,301
Ophthalmology $198,301
Thomas Newsom, Md, MD
Ophthalmology — Payments: $194,885
Ophthalmology $194,885
Don Perez, Md, MD
Ophthalmology — Payments: $146,801
Ophthalmology $146,801
Marc Peden, Md, MD
Ophthalmology — Payments: $81,565
Ophthalmology $81,565
Steven Maskin, M.d, M.D
Ophthalmology — Payments: $79,491
Ophthalmology $79,491
Dr. Ashley Crane, M.d, M.D
Ophthalmology — Payments: $31,273
Ophthalmology $31,273